(Albany, New York) – 21st Sep 2026 – DelveInsight’s latest report, “Necrotizing Enterocolitis Market Insight, Epidemiology and Market Forecast – 2036,” provides a comprehensive assessment of the Necrotizing Enterocolitis (NEC) market across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report evaluates historical and forecasted epidemiology, patient burden, treatment practices, emerging therapies, competitive intelligence, market dynamics, therapy uptake, reimbursement, pricing, and unmet medical needs through 2036.
According to DelveInsight, the Necrotizing Enterocolitis market size across the 7MM was approximately USD 30 million in 2025 and is projected to reach approximately USD 800 million by 2036, expanding at a 26% CAGR during 2026–2036. The market remains highly underserved, with no pharmaceutical therapies currently approved specifically for NEC and treatment largely centered on supportive care, nutritional management, and surgical intervention in severe cases.
Key Takeaways from the Necrotizing Enterocolitis Market
Keen to know more about the Necrotizing Enterocolitis market? Request a sample copy of the report for detailed market insights, epidemiology, treatment landscape, pipeline analysis, and competitive intelligence. https://www.delveinsight.com/sample-request/necrotizing-enterocolitis-market
Key Factors Driving the Necrotizing Enterocolitis Market
High Disease Burden in Premature Infants
Necrotizing Enterocolitis remains one of the most serious gastrointestinal emergencies affecting preterm infants. Improvements in neonatal care have increased survival among extremely premature infants, sustaining a population vulnerable to NEC and its associated complications.
NEC can progress rapidly from intestinal inflammation to ischemia, necrosis, perforation, peritonitis, sepsis, and death, creating a substantial clinical burden for neonatal intensive care units.
Significant Unmet Medical Needs
The absence of approved targeted pharmacological therapies represents one of the most important unmet needs in the NEC treatment landscape. Current management is primarily supportive, involving bowel rest, gastric decompression, broad-spectrum antibiotics, fluid and respiratory support, and total parenteral nutrition. Severe cases may require surgical intervention.
The lack of disease-modifying therapies creates opportunities for innovative treatments capable of preventing intestinal injury, modulating inflammation, or restoring healthy gut microbiota.
Growing Focus on Preventive Strategies
Because treatment options remain limited, research is increasingly focused on NEC prevention. Strategies include early exposure to colostrum and mother’s milk, optimized nutritional practices, probiotic supplementation, environmental control, and skin-to-skin care.
Microbiome modulation is receiving particular attention, with pharmaceutical-grade probiotics and live biotherapeutic products being investigated as potential approaches for reducing NEC risk.
Increasing Interest in Microbiome-based Therapies
Abnormal bacterial colonization and intestinal immaturity are important contributors to NEC pathogenesis. Consequently, therapies designed to influence the neonatal microbiome represent an emerging area of research.
IBP-9414, which contains Lactobacillus reuteri, is being developed as a pharmaceutical-grade probiotic intended to promote healthy gastrointestinal development and prevent NEC and sepsis in premature infants.
Advancing Clinical Pipeline
The NEC therapeutic pipeline is beginning to diversify beyond conventional supportive care. Late-stage and early-stage candidates are exploring probiotic, live biotherapeutic, regenerative, anti-inflammatory, and immunomodulatory approaches.
The advancement of these candidates could significantly alter the NEC market if clinical and regulatory milestones are successfully achieved.
Competitive Landscape
The NEC market remains relatively concentrated because no pharmaceutical therapy is currently approved specifically for the disease. Key companies identified by DelveInsight include:
Key emerging therapies include:
Among these candidates, IBP-9414 is the most advanced program, with the company pursuing a registration-enabling development pathway following Phase III clinical evaluation in very low birth weight infants.
Recent Developments in the Necrotizing Enterocolitis Market
What is Necrotizing Enterocolitis?
Necrotizing Enterocolitis is a severe, potentially life-threatening gastrointestinal disease that predominantly affects premature infants. It is characterized by intestinal inflammation, bacterial invasion, progressive tissue injury, and necrosis. In severe cases, intestinal perforation can lead to peritonitis, sepsis, and death.
The exact cause of NEC remains incompletely understood. However, intestinal immaturity, abnormal gut bacterial colonization, exaggerated inflammatory responses, and nutritional factors are considered important contributors to disease development.
The disease may progress from intestinal inflammation to ischemia, necrosis, and perforation. Clinical symptoms can include poor feeding, vomiting, abdominal distension or tenderness, lethargy, and apnea. Diagnosis generally involves clinical evaluation, laboratory testing, and imaging such as abdominal X-rays.
Inflammatory and immunological pathways, particularly the balance between TLR4 and TLR9 signaling, have also been implicated in NEC pathogenesis.
Current Treatment Landscape
There are currently no pharmaceutical therapies approved specifically for Necrotizing Enterocolitis. Treatment is primarily determined by disease severity and focuses on stabilization and preventing further intestinal injury.
For early-stage disease, management generally involves:
Advanced or non-responsive disease may require surgical intervention, including laparotomy, removal of necrotic bowel, ostomy, or peritoneal drainage in critically ill infants.
With limited treatment options, preventive strategies are increasingly emphasized. These include mother’s milk and colostrum feeding, optimized nutrition, probiotic use, environmental protection, and skin-to-skin care.
However, probiotic use remains inconsistent because of the lack of standardized formulations, safety considerations, and the absence of FDA-approved pharmaceutical-grade probiotic products specifically for NEC.
Necrotizing Enterocolitis Epidemiology
DelveInsight’s epidemiological assessment covers the 7MM and focuses on the burden of NEC among premature infants, particularly those with very low birth weight.
Key epidemiological findings include:
Epidemiology Segmentation
DelveInsight segments the NEC epidemiology analysis into:
Unmet Needs in Necrotizing Enterocolitis
Despite advances in neonatal care, significant unmet needs remain:
These unmet needs provide opportunities for therapies capable of preventing NEC, improving early diagnosis, reducing disease severity, and minimizing the need for surgical intervention.
Scope of the Necrotizing Enterocolitis Market Report
To Know More About the Necrotizing Enterocolitis Market Report
Necrotizing Enterocolitis Market Insight, Epidemiology and Market Forecast – 2036
Table of Contents
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in the life sciences and healthcare industries. Founded in 2014, the company provides comprehensive market intelligence, epidemiology, and insights across pharmaceuticals, biotechnology, medical devices, and emerging therapies. DelveInsight helps healthcare organizations make informed strategic decisions through data-driven research and industry expertise.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kirti SharmaEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services
